The MAC score, proposed by Waclawiczek et al. [20], uses the combined expression of BCL2 family members BCL2, MCL1, and BCL-XL to predict the response to BCL2-inhibitor venetoclax (VEN) and DNA hypomethylating agent azacitidine (AZA) combination therapy in AML patients. This evidence concerns the gene BCL2 and acute myeloid leukemia.